Good Lifestyle

Good news appeared from the modern blue biotechnology company concerning aPotential coronavirus vaccine. The vaccine is currently inFDA test protocols And is the first coronavirus vaccine test administered on human beings. Moderna revealed that this did preliminary tests on eight healthy volunteers aged 18 to 55 and, as a result of the positive results, the vaccine is now on an accelerated schedule to start a higher human trial in July.

Moderna is currently calling his candidate for the "Arna-1273" vaccine. His study, first made on mice, then on the man, was conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

The first eight participants each received two doses of the potential coronavirus vaccine from March. Two weeks after the second dose of the vaccine, theAntibody levels among participants were similar to those who have exceeded or significantly those in those who haverecovered from COVID-19. Only one subject has experienced redness around the injection site, considered an "unwanted event of grade 3". "No unwanted grade 4 test or serious adverse events has been reported," Moderna said in a press release.

"These data justify our belief that the ARNA-1273 has the potential ofPrevent COVID-19 disease, "TAL ZAKS, MD, PhD, Chief Medician of Moderna, stated in a statement.

Although we are still a way away from a coronavirus vaccine made available publicly, the Moderna vaccine will now move aggressively in the next phase of the tests. "The Moderna team continues to focus on moving as fast as possible [as] possible to start our pivoting phase 3 study in July"Stéphane BantelChief Executive Officer of Moderna, said in a statement. "We invest at the manufacturing level so that we can maximize the number of doses we can produce to help protect as many people as possible from Sars-Cov-2." And for more than one coronavirus treatment, checkAll you need to know about the new coronavirus treatment.